Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pexastimogene devacirepvec - SillaJen Biotherapeutics

Next Previous
Drug Profile

Pexastimogene devacirepvec - SillaJen Biotherapeutics

Alternative Names: JX-594; Pexa-Vec; TG-6006

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Bergonie Institute; Centre Leon Berard; GC Biopharma; Jennerex; Lee's Pharmaceutical; National Cancer Institute (France); National Cancer Institute (USA); Regeneron Pharmaceuticals; Royal Melbourne Hospital; SillaJen Biotherapeutics; Transgene; Yonsei University College of Medicine; Yonsei University Health System
  • Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Breast cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Phase I/II Colorectal cancer; Malignant melanoma
  • Preclinical Gastric cancer
  • No development reported Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 20 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Renal cell carcinoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 24 Jul 2023 Pexastimogene devacirepvec is still in phase I trials for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (Intratumoural, Injection) (NCT02977156)
  • 24 Jul 2023 SillaJen Biotherapeutics pipeline: Updated intro, KDM, reverted NDR and frwded lines to ph-I/II in RCC; NDR reverted based on NCT mentioned in the pipeline; initiated ACTRN12620001286932 trial and completed planned trial FE
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top